Revolution Medicines (RVMD) is up about 8.6% in Tuesday trading (April 28, 2026) as momentum builds around its lead RAS(ON) inhibitor daraxonrasib following a pivotal Phase 3 win in metastatic pancreatic ductal adenocarcinoma. The latest leg higher reflects investor positioning ahead of a high-profile scientific catalyst: detailed RASolute 302 results scheduled for a Plenary Session at the 2026 ASCO Annual Meeting on May 31 in Chicago. (globenewswire.com)

The company’s topline RASolute 302 readout reported daraxonrasib achieved a median overall survival of 13.2 months versus 6.7 months for standard intravenous chemotherapy, alongside strong statistical significance and a hazard ratio of 0.40 (implying a 60% reduction in risk of death). The magnitude of the survival benefit has been treated by the market as a potential practice-changing event in a cancer with limited effective second-line options, helping explain continued buying interest even weeks after the headline release. (globenewswire.com)

The near-term question is whether the full ASCO presentation confirms durability across subgroups, safety/tolerability, and the benefit-risk profile needed to support regulatory filings. Separately, the company has highlighted FDA Breakthrough Therapy Designation and Orphan Drug Designation for daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma with RAS mutations, which can support closer FDA engagement and potentially faster development timelines, but do not guarantee approval. (ascopost.com)

RVMD’s move is occurring after the company completed a large financing in mid-April, raising roughly $2.2 billion gross through concurrent upsized offerings (common stock plus convertible notes), which improves cash runway but can also create near-term supply/overhang as the market digests new issuance. With the stock now trading primarily on clinical and regulatory milestones, volatility can remain elevated into ASCO and any subsequent regulatory update cadence. (stocktitan.net)